Novartis emphasizes creating value for stakeholders and society in new integrated report

Northampton, MA –News Direct– 3BL Alerts

At Novartis, we strive to build trust with society and deliver long-term value to our stakeholders by integrating environmental, social and governance (ESG) issues into the heart of our business strategy and operations. .

In February, we released our first integrated Novartis in Society 2021 report, a new approach to reporting that describes how we are creating value for our stakeholders through our goal of reinventing medicine to improve and extend people’s lives. The report is intended for all Novartis stakeholders, while addressing the specific needs of investors and ESG professionals with comprehensive, downloadable data on our performance.

The Novartis in Society 2021 Integrated Report contains three main sections:

  • Our approach, including details of our business environment, stakeholders, strategy and risk management

  • Our performance, including financial performance and performance against our five strategic priorities: delivering transformative innovation, embracing operational excellence, leveraging data and digital, unleashing the power of our people, and building trust with company

  • Corporate governance and our approach to executive compensation


  • Significant impact on the world: Our medicines reached 766 million patients in 2021, including 56.2 million thanks to our various access to medicines approaches.

  • Delivering transformative innovation to patients: We received 21 approvals for new drugs or new indications for existing drugs in the US, EU, Japan and China. This includes two New Drug (New Molecular Entity) approvals from the United States Food and Drug Administration: one for chronic myeloid leukemia, a type of blood cancer, and the other for a new cholesterol-lowering treatment for atherosclerotic cardiovascular disease, a major public health burden. affecting 30 million Americans.

  • Advancing a strong pipeline: Our pipeline of experimental treatments, which spans approximately 50 diseases, has the potential to transform the standard of care for millions of patients worldwide. Approximately 85% of our treatments in development have the potential to be first in class or first in a specific indication. By 2026, we expect over 20 pipeline assets to be approved with the potential to become blockbuster drugs with annual sales of over $1 billion.

  • Addressing Critical Global Health Challenges: We helped develop a potential new treatment option for the COVID-19 pandemic, the most pressing public health issue in the world today, and advanced two compounds that have the potential to become the next generation of antimalarial drugs. In 2021, we also passed the milestone of one billion treatments of our existing antimalarial medicine delivered to patients in endemic countries since 1999, more than 90% of which were delivered without profit.

  • Innovating in access to medicines: Value-based pricing, sustainable business models, zero-profit models and donations are all approaches we use to support the affordability of our medicines. We are also breaking new ground in access: we announced a first global agreement with the National Health Service in England to enable wide access to our cholesterol-lowering medicine Leqvio® through a population health management approach.

  • Ensuring sustainable financial growth: We achieved a solid financial performance, supported by growth in sales of key products. Group net sales increased by 4% compared to 2020 when measured at constant exchange rates to eliminate the impact of exchange rate fluctuations (cc).

  • Transforming our culture: Our people bring our purpose to life. Employee engagement at Novartis remained consistently above the industry benchmark in 2021, as we continued to deliver a flexible work policy to meet the changing needs and expectations of our people during the COVID pandemic -19. Meanwhile, Novartis has also been included in the Bloomberg Gender-Equality Index for the third consecutive year.

  • Reducing our environmental footprint: We have strengthened our environmental targets, with a new commitment to be zero carbon emissions across our entire value chain by 2040. We have also further reduced our environmental footprint with a 34% reduction in greenhouse gas emissions. greenhouse effect (Scope 1 and Scope 2), a 40% reduction in water consumption and a 56% reduction in waste sent for disposal (all percentages compared to a 2016 baseline).

Commenting on the company’s performance in 2021, Novartis CEO Vas Narasimhan said: “Our impact on the world remains extraordinary. As we reimagine medicine at Novartis, our unwavering focus on strategy and purpose has enabled us to continue to create value for patients, healthcare professionals, healthcare systems, employees, shareholders and society. company.

Novartis’ Integrated Report in Society is prepared in accordance with key corporate reporting frameworks and guidelines, including the GRI Standards Core Option, SASB Standards, Integrated Reporting Framework and Task Force on Climate- related Financial Disclosures (TCFD).

Access and download the full report at:

Novartis Media RelationsCentral Media Line: +41 61 324 2200 Email: [email protected]

This communication contains forward-looking statements. These forward-looking statements are subject to important known and unknown risks and uncertainties. This communication also contains non-IFRS measures. For more information and an explanation of non-IFRS measures, please refer to the

Read the report

See additional media and more ESG stories from 3BL Alerts at

See the source version on

Previous India reports 27,409 new infections, daily positivity rate drops to 2.23pc
Next State Legislators to Participate in Fairfield Forum | News